Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

A novel serum marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC).

Ruzzenente A, Iacono C, Conci S, Bertuzzo F, Salvagno G, Ruzzenente O, Campagnaro T, Valdegamberi A, Pachera S, Bagante F, Guglielmi A.

Surgery. 2014 Apr;155(4):633-9. doi: 10.1016/j.surg.2013.12.003. Epub 2013 Dec 14.

PMID:
24468034
2.

MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.

Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, Batra SK, Swallow DM, Pereira SP.

Br J Cancer. 2008 May 20;98(10):1675-81. doi: 10.1038/sj.bjc.6604364. Epub 2008 May 13.

3.

Assessment of bile and serum mucin5AC in cholangiocarcinoma: diagnostic performance and biologic significance.

Danese E, Ruzzenente O, Ruzzenente A, Iacono C, Bertuzzo F, Gelati M, Conci S, Bendinelli S, Bonizzato G, Guglielmi A, Salvagno GL, Lippi G, Guidi GC.

Surgery. 2014 Nov;156(5):1218-24. doi: 10.1016/j.surg.2014.05.006. Epub 2014 Aug 21.

PMID:
25151557
4.

Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma.

Boonla C, Wongkham S, Sheehan JK, Wongkham C, Bhudhisawasdi V, Tepsiri N, Pairojkul C.

Cancer. 2003 Oct 1;98(7):1438-43.

5.

Serum MUC5AC mucin as a potential marker for cholangiocarcinoma.

Wongkham S, Sheehan JK, Boonla C, Patrakitkomjorn S, Howard M, Kirkham S, Sripa B, Wongkham C, Bhudhisawasdi V.

Cancer Lett. 2003 May 30;195(1):93-9.

PMID:
12767517
6.

Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy.

Abe T, Amano H, Shimamoto F, Hattori M, Kuroda S, Kobayashi T, Tashiro H, Ohdan H.

Eur J Surg Oncol. 2015 Nov;41(11):1515-21. doi: 10.1016/j.ejso.2015.07.006. Epub 2015 Jul 17.

PMID:
26210654
7.

A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma.

Bamrungphon W, Prempracha N, Bunchu N, Rangdaeng S, Sandhu T, Srisukho S, Boonla C, Wongkham S.

Cancer Lett. 2007 Mar 18;247(2):301-8. Epub 2006 Jun 21.

PMID:
16793202
8.

Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer.

Kishimoto T, Eguchi H, Nagano H, Kobayashi S, Akita H, Hama N, Wada H, Kawamoto K, Tomokuni A, Tomimaru Y, Umeshita K, Doki Y, Mori M.

Cancer Sci. 2013 Dec;104(12):1626-31. doi: 10.1111/cas.12300. Epub 2013 Nov 12.

9.

Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.

Dhar DK, Olde Damink SW, Brindley JH, Godfrey A, Chapman MH, Sandanayake NS, Andreola F, Mazurek S, Hasan T, Malago M, Pereira SP.

Cancer. 2013 Feb 1;119(3):575-85. doi: 10.1002/cncr.27611. Epub 2012 Aug 1.

10.

Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.

Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.

Anticancer Res. 2000 Nov-Dec;20(6D):5195-8.

PMID:
11326694
11.

Perineural invasion and preoperative serum CA19-9 as predictors of survival in biliary tract cancer.

Kawamata H, Yamashita K, Nakamura K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Kumamoto Y, Watanabe M.

Anticancer Res. 2013 Feb;33(2):583-94.

PMID:
23393352
12.

Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer.

Harder J, Kummer O, Olschewski M, Otto F, Blum HE, Opitz O.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2097-100.

13.

Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.

Leelawat K, Sakchinabut S, Narong S, Wannaprasert J.

BMC Gastroenterol. 2009 Apr 30;9:30. doi: 10.1186/1471-230X-9-30.

14.

Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.

McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ.

Eur J Cancer. 2014 Jun;50(9):1581-9. doi: 10.1016/j.ejca.2014.02.015. Epub 2014 Mar 11.

PMID:
24630393
15.

Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis.

Xu Y, Zhang L, Hu G.

Biologicals. 2009 Jan;37(1):18-25. doi: 10.1016/j.biologicals.2008.08.002. Epub 2008 Oct 10.

PMID:
18848467
16.

Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact.

Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS.

Oncol Rep. 2009 Sep;22(3):649-57.

PMID:
19639217
17.

Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival.

Shen YC, Hu FC, Jeng YM, Chang YT, Lin ZZ, Chang MC, Hsu C, Cheng AL.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):417-23. doi: 10.1158/1055-9965.EPI-08-0691. Epub 2009 Feb 3.

18.

Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.

Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A.

Oncology. 2010;79(1-2):39-45. doi: 10.1159/000318020. Epub 2010 Nov 10.

PMID:
21063134
19.

Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer.

Chung MJ, Lee KJ, Bang S, Park SW, Kim KS, Lee WJ, Song SY, Chung JB, Park JY.

Ann Surg Oncol. 2011 Jun;18(6):1651-6. doi: 10.1245/s10434-010-1529-7. Epub 2011 Jan 6.

PMID:
21210227
20.

Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas.

Wang JY, Chang CT, Hsieh JS, Lee LW, Huang TJ, Chai CY, Lin SR.

J Surg Oncol. 2003 Aug;83(4):253-60.

PMID:
12884239
Items per page

Supplemental Content

Write to the Help Desk